SCHEMBL8044674

SCHEMBL8044674

CCCCCNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
CHRM2 P08172 1/20 0.50
ADRA2A P08913 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
DRD1 P21728 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
CYP2C19 P33261 1/20 0.50
ADRA1A P35348 1/20 0.50
DRD3 P35462 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
CASP2 P42575 1/20 0.49
EYA2 O00167 1/20 0.47
APP P05067 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9654139 1.00 TDP1 (0.50) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1419591 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1420133 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL2029653 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1419654 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL2027019 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1419852 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1419840 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL2029786 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A
SCHEMBL1419475 0.98 CASP2 (0.51) TDP1KDM4ELMNACHRM2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070009442-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules SCHERING AG (DE) 2007-01-11 US disclosed
US-6080785-A REACTING A ALKYLNEDI-PRIMARY AMINE COMPOUND WITH A PROTECTIVE GROUP SUCH AS TRIFLUOROACETYL OR BENZYL GROUP REAGENT TO FORM AN INTERMEDIATE, REACTING THE INTERMEDIATE WITH HALOACETIC TERT-BYTYL ESTER TO FORM ESTER GROUPS, DEPROTECTING SCHERING AKTIENGESELLSCHAFT (DE) 2000-06-27 US disclosed
EP-0871608-B1 Monofunctionalised EDTA-, DTPA- and TTHA-Derivatives and their use for the preparation of a diagnoctic or therapeutic medicine SCHERING AG (DE) 2000-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070009442-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules CA13, MPI, CA14 TDP1 4513/4885KDM4E 3959/4885LMNA 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.